Moderna Shares Tick Up After FDA Agrees to Review Seasonal Flu Vaccine Application
Moderna shares rose following the U.S. Food and Drug Administration's decision to accept for review the company's biologics license application for its investigational seasonal influenza vaccine, mRNA-1010. The move follows a Type A meeting and a revised regulatory approach that seeks different approval pathways by age group, with a PDUFA goal date…